Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours).
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic